公开(公告)号：EP1720562A1

公开(公告)日：2006-11-15

申请号：EP05705830.7

申请日：2005-01-18

申请人： Scios, Inc.

发明人： KAPOUN, Ann, M. ,  SCHREINER, George, F. ,  LIANG, Faquan ,  LI, Zhihe

IPC分类号： A61K38/00

CPC分类号： A61K38/2242

摘要： The invention concerns methods for treating cardiac remodeling in a subject who has undergone myocardial injury, said method comprising the administration of natriuretic peptide to said subject. Preferably the natriuretic peptide is brain natriuretic peptide. The invention also concerns methods for treating structural heart disorders arising from myocardial injury, said method comprising the administration of a natriuretic peptide to a patient in need thereof.

公开(公告)号：EP1572208A2

公开(公告)日：2005-09-14

申请号：EP03789956.4

申请日：2003-11-20

申请人： Scios, Inc.

发明人： FENG, Ying ,  HIGGINS, Linda, S. ,  KAPOUN, Ann, M. ,  LIU, David, Y. ,  SCHREINER, George, F.

IPC分类号： A61K31/495 ,  A61K31/50 ,  A61K31/505

CPC分类号： A61K31/495 ,  A61K31/50 ,  A61K31/505

摘要： The invention concerns methods for modulating the ß-adrenergic pathway. In particular, the invention concerns methods for counteracting a pathologic change, such as, for example, a loss in ß-adrenergic sensitivity, in the ß-adrenergic signal transduction pathway by administering an effective amount of a compound capable of inhibiting TGF-ß signaling through a TGF-ß receptor.

公开(公告)号：EP1511738A1

公开(公告)日：2005-03-09

申请号：EP03726892.7

申请日：2003-05-16

申请人： Scios Inc.

发明人： CHAKRAVARTY, Sarvajit ,  DUGAR, Sundeep ,  HIGGINS, Linda, S. ,  KAPOUN, Ann, M. ,  LIU, David, Y. ,  SCHREINER, George, F. ,  PROTTER, Andrew, A. ,  TRAN, Thomas-Toan

IPC分类号： C07D239/42 ,  C07D239/94 ,  C07D471/04

CPC分类号： A61K31/435 ,  A61K31/495 ,  A61K31/53

摘要： The invention concerns methods of treating fibroproliferative disorders associated with TGF-β signaling, by administering non-peptide small molecule inhibitors of TGF-β specifically binding to the type I TGF-β receptor (TGFβ-R1). Preferably, the inhibitors are quinazoline derivatives. The invention also concerns methods for reversing the effect of TGF-β mediated cell activation on the expression of a gene associated with fibrosis, comprising contacting a cell or tissue in which the expression of such gene is altered as a result of TGF-β mediated cell activation, with a non-peptide small molecule inhibitor of TGF-β, specifically binding a TGFβ-R1 receptor kinase present in the cell or tissue.

公开(公告)号：EP1220916A1

公开(公告)日：2002-07-10

申请号：EP00968431.7

申请日：2000-09-27

申请人： Scios Inc.

发明人： STANTON, Lawrence, W. ,  KAPOUN, Ann, M.

IPC分类号： C12N15/12 ,  C12N15/62 ,  C07K14/47 ,  C07K16/18 ,  C12Q1/68 ,  A61K38/17

CPC分类号： C07K14/47 ,  A61K38/00 ,  C07K2319/02 ,  Y02A50/411

摘要： The invention concerns a new secreted factor encoded by clone P00188_D12, and other mammalian homologues and variants of such factor, as well as polynucleotides encoding them. The invention further concerns methods and means for producing such factors and their use in the diagnosis and treatment of various cardiac, renal or inflammatory diseases.